Lépine JP, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat. 2011;7:3–7.
Rush AJ, Warden D, Wisniewski SR, Fava M, Trivedi MH, Gaynes BN, et al. STAR*D: revising conventional wisdom. CNS Drugs. 2009;23:627–47.
Rush AJ. Limitations in efficacy of antidepressant monotherapy. J Clin Psychiatry. 2007;68:8–10.
Google Scholar
Leuchter AF, Cook IA, Hamilton SP, Narr KL, Toga A, Hunter AM, et al. Biomarkers to predict antidepressant response. Curr Psychiatry Rep. 2010;12:553–62.
Google Scholar
Altamura CA, Mauri MC, Ferrara A, Moro AR, D’Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry. 1993;150:1731–3.
Google Scholar
Yildiz-Yesiloglu A, Ankerst DP. Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res. 2006;147:1–25.
Google Scholar
Lener MS, Niciu MJ, Ballard ED, Park M, Park LT, Nugent AC, et al. Glutamate and gamma-aminobutyric acid systems in the pathophysiology of major depression and antidepressant response to Ketamine. Biol Psychiatry. 2017;81:886–97.
Google Scholar
Kim YK, Na KS. Role of glutamate receptors and glial cells in the pathophysiology of treatment-resistant depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016;70:117–26.
Google Scholar
Mathews DC, Henter ID, Zarate CA. Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs. 2012;72:1313–33.
Google Scholar
Salvadore G, van der Veen JW, Zhang Y, Marenco S, Machado-Vieira R, Baumann J, et al. An investigation of amino-acid neurotransmitters as potential predictors of clinical improvement to ketamine in depression. Int J Neuropsychopharmacol. 2012;15:1063–72.
Google Scholar
Luborzewski A, Schubert F, Seifert F, Danker-Hopfe H, Brakemeier EL, Schlattmann P, et al. Metabolic alterations in the dorsolateral prefrontal cortex after treatment with high-frequency repetitive transcranial magnetic stimulation in patients with unipolar major depression. J Psychiatr Res. 2007;41:606–15.
Google Scholar
Weckmann K, Deery MJ, Howard JA, Feret R, Asara JM, Dethloff F, et al. Ketamine’s effects on the glutamatergic and GABAergic systems: a proteomics and metabolomics study in mice. Mol Neuropsychiatry. 2019;5:42–51.
Google Scholar
Dall’Olio R, Gandolfi O, Gaggi R. D-Cycloserine, a positive modulator of NMDA receptors, inhibits serotonergic function. Behav Pharmacol. 2000;11:631–7.
Google Scholar
Kantrowitz JT, Milak MS, Mao X, Shungu DC, Mann JJ. d-Cycloserine, an NMDA glutamate receptor glycine site partial agonist, induces acute increases in brain glutamate plus glutamine and GABA comparable to Ketamine. Am J Psychiatry. 2016;173:1241–2.
Google Scholar
Abdallah CG, Niciu MJ, Fenton LR, Fasula MK, Jiang L, Black A, et al. Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder. Psychother Psychosom. 2014;83:298–307.
Google Scholar
Mosiołek A, Pietrzak M, Tabisz M, Wojtaszek W, Zabielska M, Ostrowska A, et al. Brain-derived neurotrophic factor (BDNF) as an Indicator for effects of cognitive behavioral therapy (CBT): a systematic review. Biomedicines. 2022;11:27.
Google Scholar
Mattson MP. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann N Y Acad Sci. 2008;1144:97–112.
Google Scholar
Wade-Bohleber L, Zoelch N, Lehmann M, Ernst J, Richter A, Seifritz E, et al. Effects of psychotherapy on glutamatergic neurotransmission. Neuropsychobiology. 2023;82:203–9.
Google Scholar
Ghafouri S, Fathollahi Y, Semnanian S, Shojaei A, Asgari A, Ebrahim Amini A, et al. Deep brain stimulation restores the glutamatergic and GABAergic synaptic transmission and plasticity to normal levels in kindled rats. PLoS ONE. 2019;14:e0224834.
Google Scholar
Alosaimi F, Boonstra JT, Tan S, Temel Y, Jahanshahi A. The role of neurotransmitter systems in mediating deep brain stimulation effects in Parkinson’s disease. Front Neurosci. 2022;16:998932.
Google Scholar
Croarkin PE, Levinson AJ, Daskalakis ZJ. Evidence for GABAergic inhibitory deficits in major depressive disorder. Neurosci Biobehav Rev. 2011;35:818–25.
Google Scholar
Moser A, Gieselberg A, Ro B, Keller C, Qadri F. Deep brain stimulation: response to neuronal high frequency stimulation is mediated through GABA(A) receptor activation in rats. Neurosci Lett. 2003;341:57–60.
Google Scholar
Merkl A, Schubert F, Quante A, Luborzewski A, Brakemeier EL, Grimm S, et al. Abnormal cingulate and prefrontal cortical neurochemistry in major depression after electroconvulsive therapy. Biol Psychiatry. 2011;69:772–9.
Google Scholar
Njau S, Joshi SH, Espinoza R, Leaver AM, Vasavada M, Marquina A, et al. Neurochemical correlates of rapid treatment response to electroconvulsive therapy in patients with major depression. J Psychiatry Neurosci. 2017;42:6–16.
Google Scholar
Sanacora G, Mason GF, Rothman DL, Hyder F, Ciarcia JJ, Ostroff RB, et al. Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry. 2003;160:577–9.
Google Scholar
Rojas M, Ariza D, Ortega Á, Riaño-Garzón ME, Chávez-Castillo M, Pérez JL, et al. Electroconvulsive therapy in psychiatric disorders: a narrative review exploring neuroendocrine-immune therapeutic mechanisms and clinical implications. Int J Mol Sci. 2022;23:6918.
Google Scholar
Devanand DP, Shapira B, Petty F, Kramer G, Fitzsimons L, Lerer B, et al. Effects of electroconvulsive therapy on plasma GABA. Convuls Ther. 1995;11:3–13.
Google Scholar
Voineskos D, Levinson AJ, Sun Y, Barr MS, Farzan F, Rajji TK, et al. The Relationship between cortical inhibition and electroconvulsive therapy in the treatment of major depressive disorder. Sci Rep. 2016;6:37461.
Google Scholar
Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry. 2002;159:663–5.
Google Scholar
Colic L, von During F, Denzel D, Demenescu LR, Lord AR, Martens L, et al. Rostral anterior cingulate glutamine/glutamate disbalance in major depressive disorder depends on symptom severity. Biol Psychiatry Cogn Neurosci Neuroimaging. 2019;4:1049–58.
Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry. 2003;53:649–59.
Google Scholar
Narayan GA, Hill KR, Wengler K, He X, Wang J, Yang J, et al. Does the change in glutamate to GABA ratio correlate with change in depression severity? a randomized, double-blind clinical trial. Mol Psychiatry. 2022;27:3833–41.
Google Scholar
El-Baba RM, Schury MP. Neuroanatomy, Frontal Cortex, 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
Kummer KK, Mitrić M, Kalpachidou T, Kress M. The medial prefrontal cortex as a central hub for mental comorbidities associated with chronic pain. Int J Mol Sci. 2020;21:3440.
Google Scholar
Bittar TP, Labonté B. Functional contribution of the medial prefrontal circuitry in major depressive disorder and stress-induced depressive-like behaviors. Front Behav Neurosci. 2021;15:699592.
Google Scholar
Kim M, Kim W, Chung C. The neural basis underlying female vulnerability to depressive disorders. Anim Cells Syst. 2023;27:297–308.
Google Scholar
Morris LS, Costi S, Tan A, Stern ER, Charney DS, Murrough JW. Ketamine normalizes subgenual cingulate cortex hyper-activity in depression. Neuropsychopharmacology. 2020;45:975–81.
Google Scholar
Wagner G, Koch K, Schachtzabel C, Peikert G, Schultz CC, Reichenbach JR, et al. Self-referential processing influences functional activation during cognitive control: an fMRI study. Soc Cogn Affect Neurosci. 2013;8:828–37.
Google Scholar
Bartlett EA, DeLorenzo C, Sharma P, Yang J, Zhang M, Petkova E, et al. Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. Neuropsychopharmacology. 2018;43:2221–30.
Google Scholar
Kirsch I. Antidepressants and the placebo effect. Z Psychol. 2014;222:128–34.
Barbui C, Furukawa TA, Cipriani A. Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ. 2008;178:296–305.
Google Scholar
Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287:1840–7.
Google Scholar
Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002;159:728–37.
Google Scholar
Smith GS, Kramer E, Hermann C, Ma Y, Dhawan V, Chaly T, et al. Serotonin modulation of cerebral glucose metabolism in depressed older adults. Biol Psychiatry. 2009;66:259–66.
Google Scholar
Sikora M, Heffernan J, Avery ET, Mickey BJ, Zubieta JK, Peciña M. Salience network functional connectivity predicts placebo effects in major depression. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1:68–76.
Benedetti F, Mayberg HS, Wager TD, Stohler CS, Zubieta JK. Neurobiological mechanisms of the placebo effect. J Neurosci. 2005;25:10390–402.
Google Scholar
Rutherford BR, Wager TD, Roose SP. Expectancy and the treatment of depression: a review of experimental methodology and effects on patient outcome. Curr Psychiatry Rev. 2010;6:1–10.
Google Scholar
Rutherford BR, Wall MM, Brown PJ, Choo TH, Wager TD, Peterson BS, et al. Patient Expectancy as a mediator of placebo effects in antidepressant clinical trials. Am J Psychiatry. 2017;174:135–42.
Google Scholar
Zilcha-Mano S, Wang Z, Peterson BS, Wall MM, Chen Y, Wager TD, et al. Neural mechanisms of expectancy-based placebo effects in antidepressant clinical trials. J Psychiatr Res. 2019;116:19–25.
Google Scholar
Ciftci A, Ulas H, Topuzoglu A, Tunca Z. Is the ultimate treatment response predictable with early response in major depressive episode? Noro Psikiyatr Ars. 2016;53:245–52.
Google Scholar
Rojo JE, Gibert K, Cobo J, Rodriguez-Cano E, Vallejo J. Onset of antidepressant action: a pharmacological question? Hum Psychopharmacol. 2005;20:425–33.
Google Scholar
Grunebaum MF, Ellis SP, Li S, Oquendo MA, Mann JJ. Antidepressants and suicide risk in the United States, 1985–1999. J Clin Psychiatry. 2004;65:1456–62.
Google Scholar
Katon W, Unutzer J, Russo J. Major depression: the importance of clinical characteristics and treatment response to prognosis. Depress Anxiety. 2010;27:19–26.
Google Scholar
Chaki S, Fukumoto K. mGlu receptors as potential targets for novel antidepressants. Curr Opin Pharmacol. 2018;38:24–30.
Google Scholar
Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron. 2019;102:75–90.
Google Scholar
First MB, Gibbon M, Spitzer RL, Williams JBW, Benjamin LS. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). (Washington, DC: American Psychiatric Press, Inc., 1997).
First MB, Spitzer RL, Gibbon M, Williams J. Structured clinical interview for DSM-IV-TR Axis I disorders, research version. Biometrics Research, (New York State Psychiatric Institute, New York, 2002).
Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–9.
Google Scholar
Gorwood P, Weiller E, Lemming O, Katona C. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry. 2007;15:581–93.
Google Scholar
Hill KR, Gardus JD, Bartlett EA, Perlman G, Parsey RV, DeLorenzo C. Measuring brain glucose metabolism in order to predict response to antidepressant or placebo: a randomized clinical trial. NeuroImage Clin. 2021;32:102858.
Google Scholar
Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998;11:266–72.
Google Scholar
Edden RA, Puts NA, Harris AD, Barker PB, Evans CJ. Gannet: a batch-processing tool for the quantitative analysis of gamma-aminobutyric acid-edited MR spectroscopy spectra. J Magn Reson Imaging. 2014;40:1445–52.
Google Scholar
Klose U. In vivo proton spectroscopy in presence of eddy currents. Magn Reson Med. 1990;14:26–30.
Google Scholar
Near J, Edden R, Evans CJ, Paquin R, Harris A, Jezzard P. Frequency and phase drift correction of magnetic resonance spectroscopy data by spectral registration in the time domain. Magn Reson Med. 2015;73:44–50.
Google Scholar
Wilson M, Reynolds G, Kauppinen RA, Arvanitis TN, Peet AC. A constrained least-squares approach to the automated quantitation of in vivo (1)H magnetic resonance spectroscopy data. Magn Reson Med. 2011;65:1–12.
Google Scholar
Keysers C, Gazzola V, Wagenmakers EJ. Using Bayes factor hypothesis testing in neuroscience to establish evidence of absence. Nat Neurosci. 2020;23:788–99.
Google Scholar
Khan A, Brown WA. Antidepressants versus placebo in major depression: an overview. World Psychiatry. 2015;14:294–300.
Google Scholar
Holper L, Hengartner MP. Comparative efficacy of placebos in short-term antidepressant trials for major depression: a secondary meta-analysis of placebo-controlled trials. BMC Psychiatry. 2020;20:437.
Google Scholar
Sonawalla SB, Rosenbaum JF. Placebo response in depression. Dialogues Clin Neurosci. 2002;4:105–13.
Google Scholar
Jones JS, Goldstein SJ, Wang J, Gardus J, Yang J, Parsey RV, et al. Evaluation of brain structure and metabolism in currently depressed adults with a history of childhood trauma. Transl Psychiatry. 2022;12:392.
Google Scholar
Brennan BP, Admon R, Perriello C, LaFlamme EM, Athey AJ, Pizzagalli DA, et al. Acute change in anterior cingulate cortex GABA, but not glutamine/glutamate, mediates antidepressant response to citalopram. Psychiatry Res Neuroimaging. 2017;269:9–16.
Google Scholar
Cano M, Martínez-Zalacaín I, Bernabéu-Sanz Á, Contreras-Rodríguez O, Hernández-Ribas R, Via E, et al. Brain volumetric and metabolic correlates of electroconvulsive therapy for treatment-resistant depression: a longitudinal neuroimaging study. Transl Psychiatry. 2017;7:e1023.
Google Scholar
Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC. Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry. 2007;64:193–200.
Google Scholar
Dubin MJ, Mao X, Banerjee S, Goodman Z, Lapidus KA, Kang G, et al. Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy. J Psychiatry Neurosci. 2016;41:E37–45.
Google Scholar
Godfrey KEM, Muthukumaraswamy SD, Stinear CM, Hoeh N. Effect of rTMS on GABA and glutamate levels in treatment-resistant depression: An MR spectroscopy study. Psychiatry Res Neuroimaging. 2021;317:111377.
Google Scholar
Clark DL, MacMaster FP, Brown EC, Kiss ZHT, Ramasubbu R. Rostral anterior cingulate glutamate predicts response to subcallosal deep brain stimulation for resistant depression. J Affect Disord. 2020;266:90–94.
Google Scholar
Rothman DL, De Feyter HM, de Graaf RA, Mason GF, Behar KL. 13C MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed. 2011;24:943–57.
Google Scholar
Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, et al. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry. 2004;61:705–13.
Google Scholar
Godfrey KEM, Gardner AC, Kwon S, Chea W, Muthukumaraswamy SD. Differences in excitatory and inhibitory neurotransmitter levels between depressed patients and healthy controls: a systematic review and meta-analysis. J Psychiatr Res. 2018;105:33–44.
Google Scholar
Jones BDM, Razza LB, Weissman CR, Karbi J, Vine T, Mulsant LS, et al. Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis. JAMA Netw Open. 2021;4:e2125531.
Google Scholar
Cusin C, Colloca L. Treatment-resistant depression-resistant to placebos as well? JAMA Netw Open. 2021;4:e2127952.
Google Scholar
Runia N, Yücel DE, Lok A, de Jong K, Denys D, van Wingen GA, et al. The neurobiology of treatment-resistant depression: a systematic review of neuroimaging studies. Neurosci Biobehav Rev. 2022;132:433–48.
Google Scholar
Kelley ME, Dunlop BW, Nemeroff CB, Lori A, Carrillo-Roa T, Binder EB, et al. Response rate profiles for major depressive disorder: characterizing early response and longitudinal nonresponse. Depress Anxiety. 2018;35:992–1000.
Google Scholar
Niitsu T, Fabbri C, Bentini F, Serretti A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:183–94.
Google Scholar
Breitenstein B, Scheuer S, Holsboer F. Are there meaningful biomarkers of treatment response for depression? Drug Discov Today. 2014;19:539–61.
Google Scholar
Deelchand DK, Kantarci K, Öz G. Improved localization, spectral quality, and repeatability with advanced MRS methodology in the clinical setting. Magn Reson Med. 2018;79:1241–50.
Google Scholar
Shams Z, van der Kemp WJM, Emir U, Dankbaar JW, Snijders TJ, de Vos FYF, et al. Comparison of 2-hydroxyglutarate detection with sLASER and MEGA-sLASER at 7T. Front Neurol. 2021;12:718423.
Google Scholar
Pradhan S, Bonekamp S, Gillen JS, Rowland LM, Wijtenburg SA, Edden RA, et al. Comparison of single voxel brain MRS AT 3T and 7T using 32-channel head coils. Magn Reson Imaging. 2015;33:1013–8.
Google Scholar
Marsman A, Boer VO, Luijten PR, Hulshoff Pol HE, Klomp DWJ, Mandl RCW. Detection of glutamate alterations in the human brain using (1)H-MRS: comparison of STEAM and sLASER at 7 T. Front Psychiatry. 2017;8:60.
Google Scholar
Saunders R, Cohen ZD, Ambler G, DeRubeis RJ, Wiles N, Kessler D, et al. A patient stratification approach to identifying the likelihood of continued chronic depression and relapse following treatment for depression. J Pers Med. 2021;11:1295.
Google Scholar
Gunn J, Wachtler C, Fletcher S, Davidson S, Mihalopoulos C, Palmer V, et al. Target-D: a stratified individually randomized controlled trial of the diamond clinical prediction tool to triage and target treatment for depressive symptoms in general practice: study protocol for a randomized controlled trial. Trials. 2017;18:342.
Google Scholar
Buch AM, Liston C. Dissecting diagnostic heterogeneity in depression by integrating neuroimaging and genetics. Neuropsychopharmacology. 2021;46:156–75.
Google Scholar
Weinberger AH, McKee SA, Mazure CM. Inclusion of women and gender-specific analyses in randomized clinical trials of treatments for depression. J Womens Health. 2010;19:1727–32.
Google Scholar
Block W, Träber F, von Widdern O, Metten M, Schild H, Maier W, et al. Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response. Int J Neuropsychopharmacol. 2009;12:415–22.
Google Scholar
Evans JW, Lally N, An L, Li N, Nugent AC, Banerjee D, et al. 7T (1)H-MRS in major depressive disorder: a ketamine treatment study. Neuropsychopharmacology. 2018;43:1908–14.
Google Scholar
Bhattacharyya P, Anand A, Lin J, Altinay M. Left dorsolateral prefrontal cortex Glx/tCr predicts efficacy of high frequency 4- to 6-week rtms treatment and is associated with symptom improvement in adults with major depressive disorder: findings from a pilot study. Front Psychiatry. 2021;12:665347.
Google Scholar
Dong Z, Grunebaum MF, Lan MJ, Wagner V, Choo TH, Milak MS, et al. Relationship of brain glutamate response to D-cycloserine and lurasidone to antidepressant response in bipolar depression: a pilot study. Front Psychiatry. 2021;12:653026.
Google Scholar
Ermis C, Aydin B, Kucukguclu S, Yurt A, Renshaw PF, Yildiz A. Association between anterior cingulate cortex neurochemical profile and clinical remission after electroconvulsive treatment in major depressive disorder: a longitudinal 1h magnetic resonance spectroscopy study. J ECT. 2021;37:263–9.
Google Scholar
Gonsalves MA, White TL, Barredo J, DeMayo MM, DeLuca E, Harris AD, et al. Cortical glutamate, Glx, and total N-acetylaspartate: potential biomarkers of repetitive transcranial magnetic stimulation treatment response and outcomes in major depression. Transl Psychiatry. 2024;14:5.
Google Scholar
